Early Cancer Pre-Screening and 100+ Disease Risk Signals

Join the international rollout of a lab-result-based medical decision-support system that can signal tumor risk already at around 1 million cells!

The EnzyMark AI Lab Standard offers business, laboratory, and territorial partners the opportunity to join a healthcare ecosystem built on nearly 60,000 patient results and approximately 60 years of scientific and clinical development.

The goal of the cooperation is the business rollout of early cancer pre-screening, 100+ disease-risk signals, 3-second post-surgery medical feedback, and tumor-risk signaling already at around 1 million cells.

Healthcare partners preparing for growth are looking for a system that is medically valuable, clear as a business opportunity, and suitable for international markets.

A healthcare opportunity is needed that is built on real lab results, not only on theoretical promises.
Partners are looking for a solution that is easy to understand internationally and can be introduced in several countries.
Laboratories and healthcare partner networks want a new service that can create new revenue opportunities alongside their existing operations.
Investors and strategic partners are looking for a project with a long development history, a large case base, and a clear market direction.
Referrals, client acquisition, and territorial partners are seeking a cooperation model that not only enables a one-time introduction but also fosters long-term interest.

Most healthcare innovations are hard for business partners to understand, slow to introduce, and often unclear about how they will translate into real revenue.

Many healthcare projects are overly complicated, making it hard for partners to see what can actually be introduced or sold.
Many new solutions can only be understood by a narrow professional audience, which makes international business rollout difficult.
Laboratories often do not adopt new services that fit their existing infrastructure and generate real additional revenue.
Investors often encounter projects that are too early or insufficiently proven, lacking decades of professional background and a large case base.
Referral and territorial partners are often given only a one-time intermediary role, even though a well-built model could also give them a lasting revenue interest.

The EnzyMark AI Lab Standard offers a lab-result-based medical decision-support system for business, medical, laboratory, and territorial partners.

The EnzyMark AI Lab Standard is a healthcare decision-support ecosystem built on early cancer pre-screening and lab-result-based risk signals for 100+ diseases.

The system is not simply a new lab test, but a medical and business model that laboratory partners, doctors, healthcare partner networks, investors, referral partners, and territorial partners can join.

EnzyMark works with existing lab data to identify risk-related changes and lab-result connections that can help doctors determine next steps.

For partners, this is also clear from a business perspective, as the system starts with measurable lab results rather than general healthcare claims.

EnzyMark provides the necessary knowledge, medical guidance, and system needed for rollout, while local partners can join through financing, laboratory work, client acquisition, or territorial rollout.

For laboratory partners, EnzyMark can create a new service direction that may generate new revenue opportunities alongside their existing laboratory operations.

For investors, strategic partners, and territorial partners, the project's value derives from nearly 60,000 patient results, approximately 60 years of scientific and clinical development, and a business model suitable for international rollout.

The strongest benefits of the system appear in cancer pre-screening and post-surgery therapy monitoring.

In cancer pre-screening, EnzyMark can detect risk-related patterns in around 1 million tumor cells, whereas many traditional tumor markers typically become detectable only at around 1 billion tumor cells.

This difference is important because earlier risk signals can give laboratories and healthcare partners more valuable service opportunities.

The measurable results related to cancer pre-screening include sensitivity of up to 98.6%, approximately 95% clinical agreement, and 99.9% reliability.

In the case of 100+ diseases, the value of the system does not appear as a diagnosis but as lab-result-based risk signaling that can be part of medical decision support.

The EnzyMark AI Lab Standard does not diagnose, but provides early risk signals that can help doctors determine the next steps.

One of EnzyMark’s strongest benefits is that it can give doctors almost immediate feedback after surgery.

After surgery, once the effects of the anesthetics have worn off, the lab results from a blood sample can be entered into the EnzyMark system.

After surgery, the system can show the doctor, in approximately 3 seconds, the direction and extent of the change in the patient’s state, as indicated by lab results.

This is a very important benefit because currently known fast surgical or post-surgery solutions typically rely on tissue samples, blood gas parameters, or molecular blood tests performed weeks later.

EnzyMark, on the other hand, can provide a very fast overall picture from lab results, giving the doctor practically immediate feedback on how the surgery changed the patient’s state.

This is especially important for laboratories and healthcare partners because they not only receive a new testing opportunity but also a service that provides fast, clear, and useful medical feedback after surgery.

The system's special value comes, among other things, from its large case base, long development history, and processing of real patient material.

The system is based on experience gathered over approximately 60 years, from nearly 60,000 cases.

This included the examination experience of 23,000 known cancer patients, 31,000 paid examinations with unknown status, 10,000+ validated measurements, and 3,000+ cases already evaluated by AI under close medical and professional supervision.

In pre-screening for cancer risks, the system’s clinical agreement is approximately 95%, its sensitivity up to 98.6%, and its operational reliability approximately 99.9%.

In a laboratory operating in a district of 20,000 people, more than 3,000 measurements were carried out over 6 years, which meant nearly 50 clients per month.

The EnzyMark AI Lab Standard can offer laboratories significant revenue and profit potential while providing clients with high-value early risk information at an affordable price.

EnzyMark developed from several decades of clinical and scientific work into a system that is now also an attractive model for business partners.

The EnzyMark method was born of the work of an exceptional, highly practical inventor who spent more than 50 years analyzing clinical and laboratory patterns.

During his work, the experience of nearly 60,000 measurements and cases was built into the system, not as theoretical research, but through real, daily patient data processing.

The goal throughout was to make cellular-level changes visible long before symptoms and late markers appear.

From EnzyMark AI's perspective, it is especially important that more than 3,000 measurements have already been evaluated by AI under close medical and professional supervision.

The value of the scientific background lies in the fact that EnzyMark is not based on a single marker, but on the connections between lab results.

The EnzyMark approach is based on the fact that enzymatic patterns respond to cellular-level changes much earlier than traditionally used tumor markers.

Changes in enzyme function often appear much earlier than changes detectable by tissue-based or imaging tools.

The EnzyMark AI Lab Standard analyzes these early biochemical signals and looks not at a single abnormal value, but at how the changes appear together.

The system does not examine a single biomarker, but analyzes complex patterns that may already show changes at the level of one million, that is 10⁶ cells, compared with classic solutions that typically signal only at the level of one billion, that is 10⁹ cells.

This makes very early risk warning, high sensitivity, and documented, stable accuracy possible.

The EnzyMark AI Lab Standard does not work as a single standalone offer, but as a full ecosystem built around different types of participants.

The EnzyMark AI Lab Standard is for potential clients and users.
The EnzyMark AI for Doctors presents EnzyMark AI for physicians.
The EnzyMark AI for Laboratories is built on local testing, lab result production, and new service and revenue opportunities for laboratories.
The EnzyMark AI Institutional-user project enables institutional-level application.
The EnzyMark AI Database Partnership generates a large number of new clients through partnerships with large databases.
We also invite a number of Small and Angel investors to join the system; the project you are now reading is for small investors, business partners, and referral partners.
The EnzyMark AI for larger institutional investors and Family Offices offers an opportunity to finance the international rollout, expand into new territories, and create larger strategic partnerships.
The EnzyMark AI Referral Program connects all of this at the network level with a continuous, recurring, and inheritable commission system.
An additional element of the ecosystem is the Renaissance ACT Health Estate, which connects early detection, oncology care, and regeneration in an integrated environment.

You can also join the EnzyMark system as a referral partner or business partner.

The partner model allows several different roles, so joining is not limited to one single business form.

We offer revenue-sharing partner cooperation, in which the joining partner may receive a share of the project’s actual revenues under individually agreed contractual terms.

We also offer referral and client acquisition cooperation, in which the partner may receive a share of the revenue generated by the new clients, business partners, laboratory partners, strategic partners, or investors they bring to the project, under individually agreed contractual terms.

The financing and client acquisition partnership can be attractive because the joining partner can participate both on the revenue side of a project, supporting growth, and in bringing the project to international markets.

Join the rollout of the EnzyMark AI Lab Standard as an investor, laboratory partner, referral partner, client acquisition partner, or territorial partner!

Learn about the EnzyMark AI Lab Standard investment opportunity if you would like to join a healthcare decision-support system preparing for growth as a capital partner!
Request a laboratory partner discussion if you have a laboratory, healthcare provider or partner network that could take part in the local rollout!
Indicate your interest in referrals or client acquisition if you can connect new clients, business partners, laboratory partners, strategic partners, or investors to the project!
Ask about city, regional, or national territorial opportunities if you would like to take part in building up a specific market!
Start a strategic partner discussion if you can add value to the project from a healthcare, laboratory market, investment, or international rollout perspective!

Why can it be beneficial to join now as a business partner?

The joining partner can stand beside a project that has a large case base, a long development history, and a clear healthcare focus.
The laboratory partner can receive a new service direction that may create additional revenue opportunities alongside its existing operations.
The referral or client acquisition partner does not have to think only in terms of a one-time introduction, but can also have a contractually agreed revenue interest.
The territorial or strategic partner can join at an early stage of the international rollout, when city, regional, and national roles can still be shaped.

Join the international rollout of the EnzyMark AI Lab Standard on time, and take part in building a lab-result-based healthcare decision-support system in the business, laboratory market, or territorial side!

Contact us and let’s discuss how you can join the EnzyMark AI Lab Standard project as an investor, laboratory partner, referral partner, client acquisition partner, or territorial partner: [email protected]

Early Cancer Pre-Screening and 100+ Disease Risk Signals

Join the international rollout of a lab-result-based medical decision-support system that can signal tumor risk already at around 1 million cells!

The EnzyMark AI Lab Standard offers business, laboratory, and territorial partners the opportunity to join a healthcare ecosystem built on nearly 60,000 patient results and approximately 60 years of scientific and clinical development.

The goal of the cooperation is the business rollout of early cancer pre-screening, 100+ disease-risk signals, 3-second post-surgery medical feedback, and tumor-risk signaling already at around 1 million cells.

Healthcare partners preparing for growth are looking for a system that is medically valuable, clear as a business opportunity, and suitable for international markets.

Most healthcare innovations are hard for business partners to understand, slow to introduce, and often unclear about how they will translate into real revenue.

The EnzyMark AI Lab Standard offers a lab-result-based medical decision-support system for business, medical, laboratory, and territorial partners.

The EnzyMark AI Lab Standard is a healthcare decision-support ecosystem built on early cancer pre-screening and lab-result-based risk signals for 100+ diseases.

The system is not simply a new lab test, but a medical and business model that laboratory partners, doctors, healthcare partner networks, investors, referral partners, and territorial partners can join.

EnzyMark works with existing lab data to identify risk-related changes and lab-result connections that can help doctors determine next steps.

For partners, this is also clear from a business perspective, as the system starts with measurable lab results rather than general healthcare claims.

EnzyMark provides the necessary knowledge, medical guidance, and system needed for rollout, while local partners can join through financing, laboratory work, client acquisition, or territorial rollout.

For laboratory partners, EnzyMark can create a new service direction that may generate new revenue opportunities alongside their existing laboratory operations.

For investors, strategic partners, and territorial partners, the project's value derives from nearly 60,000 patient results, approximately 60 years of scientific and clinical development, and a business model suitable for international rollout.

The strongest benefits of the system appear in cancer pre-screening and post-surgery therapy monitoring.

In cancer pre-screening, EnzyMark can detect risk-related patterns in around 1 million tumor cells, whereas many traditional tumor markers typically become detectable only at around 1 billion tumor cells.

This difference is important because earlier risk signals can give laboratories and healthcare partners more valuable service opportunities.

The measurable results related to cancer pre-screening include sensitivity of up to 98.6%, approximately 95% clinical agreement, and 99.9% reliability.

In the case of 100+ diseases, the value of the system does not appear as a diagnosis but as lab-result-based risk signaling that can be part of medical decision support.

The EnzyMark AI Lab Standard does not diagnose, but provides early risk signals that can help doctors determine the next steps.

One of EnzyMark’s strongest benefits is that it can give doctors almost immediate feedback after surgery.

After surgery, once the effects of the anesthetics have worn off, the lab results from a blood sample can be entered into the EnzyMark system.

After surgery, the system can show the doctor, in approximately 3 seconds, the direction and extent of the change in the patient’s state, as indicated by lab results.

This is a very important benefit because currently known fast surgical or post-surgery solutions typically rely on tissue samples, blood gas parameters, or molecular blood tests performed weeks later.

EnzyMark, on the other hand, can provide a very fast overall picture from lab results, giving the doctor practically immediate feedback on how the surgery changed the patient’s state.

This is especially important for laboratories and healthcare partners because they not only receive a new testing opportunity but also a service that provides fast, clear, and useful medical feedback after surgery.

The system's special value comes, among other things, from its large case base, long development history, and processing of real patient material.

The system is based on experience gathered over approximately 60 years, from nearly 60,000 cases.

This included the examination experience of 23,000 known cancer patients, 31,000 paid examinations with unknown status, 10,000+ validated measurements, and 3,000+ cases already evaluated by AI under close medical and professional supervision.

In pre-screening for cancer risks, the system’s clinical agreement is approximately 95%, its sensitivity up to 98.6%, and its operational reliability approximately 99.9%.

In a laboratory operating in a district of 20,000 people, more than 3,000 measurements were carried out over 6 years, which meant nearly 50 clients per month.

The EnzyMark AI Lab Standard can offer laboratories significant revenue and profit potential while providing clients with high-value early risk information at an affordable price.

EnzyMark developed from several decades of clinical and scientific work into a system that is now also an attractive model for business partners.

The EnzyMark method was born of the work of an exceptional, highly practical inventor who spent more than 50 years analyzing clinical and laboratory patterns.

During his work, the experience of nearly 60,000 measurements and cases was built into the system, not as theoretical research, but through real, daily patient data processing.

The goal throughout was to make cellular-level changes visible long before symptoms and late markers appear.

From EnzyMark AI's perspective, it is especially important that more than 3,000 measurements have already been evaluated by AI under close medical and professional supervision.

The value of the scientific background lies in the fact that EnzyMark is not based on a single marker, but on the connections between lab results.

The EnzyMark approach is based on the fact that enzymatic patterns respond to cellular-level changes much earlier than traditionally used tumor markers.

Changes in enzyme function often appear much earlier than changes detectable by tissue-based or imaging tools.

The EnzyMark AI Lab Standard analyzes these early biochemical signals and looks not at a single abnormal value, but at how the changes appear together.

The system does not examine a single biomarker, but analyzes complex patterns that may already show changes at the level of one million, that is 10⁶ cells, compared with classic solutions that typically signal only at the level of one billion, that is 10⁹ cells.

This makes very early risk warning, high sensitivity, and documented, stable accuracy possible.

The EnzyMark AI Lab Standard does not work as a single standalone offer, but as a full ecosystem built around different types of participants.

You can also join the EnzyMark system as a referral partner or business partner.

The partner model allows several different roles, so joining is not limited to one single business form.

We offer revenue-sharing partner cooperation, in which the joining partner may receive a share of the project’s actual revenues under individually agreed contractual terms.

We also offer referral and client acquisition cooperation, in which the partner may receive a share of the revenue generated by the new clients, business partners, laboratory partners, strategic partners, or investors they bring to the project, under individually agreed contractual terms.

The financing and client acquisition partnership can be attractive because the joining partner can participate both on the revenue side of a project, supporting growth, and in bringing the project to international markets.

Join the rollout of the EnzyMark AI Lab Standard as an investor, laboratory partner, referral partner, client acquisition partner, or territorial partner!

Learn about the EnzyMark AI Lab Standard investment opportunity if you would like to join a healthcare decision-support system preparing for growth as a capital partner!

Request a laboratory partner discussion if you have a laboratory, healthcare provider or partner network that could take part in the local rollout!

Indicate your interest in referrals or client acquisition if you can connect new clients, business partners, laboratory partners, strategic partners, or investors to the project!

Ask about city, regional, or national territorial opportunities if you would like to take part in building up a specific market!

Start a strategic partner discussion if you can add value to the project from a healthcare, laboratory market, investment, or international rollout perspective!

Why can it be beneficial to join now as a business partner?

Join the international rollout of the EnzyMark AI Lab Standard on time, and take part in building a lab-result-based healthcare decision-support system in the business, laboratory market, or territorial side!

Contact us and let’s discuss how you can join the EnzyMark AI Lab Standard project as an investor, laboratory partner, referral partner, client acquisition partner, or territorial partner: [email protected]